CN109689036B - 用于治疗早晨运动不能的脉冲药物输送系统 - Google Patents

用于治疗早晨运动不能的脉冲药物输送系统

Info

Publication number
CN109689036B
CN109689036B CN201780055569.XA CN201780055569A CN109689036B CN 109689036 B CN109689036 B CN 109689036B CN 201780055569 A CN201780055569 A CN 201780055569A CN 109689036 B CN109689036 B CN 109689036B
Authority
CN
China
Prior art keywords
levodopa
minutes
dosage form
pulsatile release
lag time
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201780055569.XA
Other languages
English (en)
Chinese (zh)
Other versions
CN109689036A (zh
Inventor
J·B·汉森
M·S·汤姆森
A·V·富勒顿
本特·霍嘉德
P·G·尼尔森
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cantra Pharmaceutical Co ltd
Original Assignee
Solural Pharma ApS
Cantra Pharmaceutical Co ltd
CONCIT PHARMA APS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Solural Pharma ApS, Cantra Pharmaceutical Co ltd, CONCIT PHARMA APS filed Critical Solural Pharma ApS
Publication of CN109689036A publication Critical patent/CN109689036A/zh
Application granted granted Critical
Publication of CN109689036B publication Critical patent/CN109689036B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
CN201780055569.XA 2016-07-11 2017-07-11 用于治疗早晨运动不能的脉冲药物输送系统 Active CN109689036B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA201670516 2016-07-11
DKPA201670516 2016-07-11
PCT/EP2017/067348 WO2018011181A1 (en) 2016-07-11 2017-07-11 Pulsatile drug delivery system for treating morning akinesia

Publications (2)

Publication Number Publication Date
CN109689036A CN109689036A (zh) 2019-04-26
CN109689036B true CN109689036B (zh) 2026-06-19

Family

ID=59383543

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780055569.XA Active CN109689036B (zh) 2016-07-11 2017-07-11 用于治疗早晨运动不能的脉冲药物输送系统

Country Status (9)

Country Link
US (3) US11975104B2 (cg-RX-API-DMAC7.html)
EP (2) EP4674433A3 (cg-RX-API-DMAC7.html)
JP (3) JP7227896B2 (cg-RX-API-DMAC7.html)
KR (1) KR102443161B1 (cg-RX-API-DMAC7.html)
CN (1) CN109689036B (cg-RX-API-DMAC7.html)
AU (3) AU2017297718B2 (cg-RX-API-DMAC7.html)
CA (1) CA3030089C (cg-RX-API-DMAC7.html)
ES (1) ES3041483T3 (cg-RX-API-DMAC7.html)
WO (1) WO2018011181A1 (cg-RX-API-DMAC7.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109689036B (zh) * 2016-07-11 2026-06-19 康特拉医药股份有限公司 用于治疗早晨运动不能的脉冲药物输送系统
JP7066351B2 (ja) * 2017-08-18 2022-05-13 大原薬品工業株式会社 良好な徐放性を有する、レボドパ含有小型化錠剤
EP3968980A1 (en) 2019-05-14 2022-03-23 Clexio Biosciences Ltd. Treatment of nocturnal symptoms and morning akinesia in subjects with parkinson's disease
EP3975999A4 (en) 2019-06-03 2023-07-19 Theriva Biologics, Inc. ALKALINE PHOSPHATASE FORMULATIONS AND THEIR USES
EP3854385A1 (en) 2020-01-27 2021-07-28 ROS Therapeutics ApS Methotrexate dosage form
CN111084777A (zh) * 2020-02-11 2020-05-01 山西卫生健康职业学院 一种吡贝地尔、左旋多巴与苄丝肼复方缓释三层片剂及其制备方法
US12194150B2 (en) * 2020-12-22 2025-01-14 Amneal Pharmaceuticals Llc Levodopa dosing regimen
KR102903389B1 (ko) * 2022-11-30 2025-12-23 주식회사한국파마 신경퇴행성 질환 예방 또는 치료용 필름코팅정제
EP4631499A4 (en) * 2022-12-05 2026-04-01 Shanghai Wd Pharmaceutical Co Ltd DELAYED-RELEASE PHARMACEUTICAL COMPOSITION, RELATED PREPARATION PROCESS AND ASSOCIATED USE
WO2025172348A1 (en) * 2024-02-12 2025-08-21 Contera Pharma A/S Delayed dual-pulse oral formulation
US12466883B1 (en) 2024-05-13 2025-11-11 Lumen Bioscience, Inc. Leptin compositions and methods of making and using the same to support weight loss and/or maintenance

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101636153A (zh) * 2007-03-15 2010-01-27 波利化学公司 时间特异性延迟/脉冲释放剂型

Family Cites Families (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3253023A (en) 1963-09-27 1966-05-24 Dow Chemical Co Recovery of 3-(3, 4-dihydroxyphenyl)-l-alanine from velvet beans
BE759371A (fr) 1969-11-24 1971-05-24 Bristol Myers Co Azaspirodecanediones heterocycliques et procedes pour leur preparation
US3976776A (en) 1972-12-06 1976-08-24 Mead Johnson & Company Tranquilizer process employing N-(heteroarcyclic)piperazinylalkylazaspiroalkanediones
US4166452A (en) 1976-05-03 1979-09-04 Generales Constantine D J Jr Apparatus for testing human responses to stimuli
US4182763A (en) 1978-05-22 1980-01-08 Mead Johnson & Company Buspirone anti-anxiety method
US4356108A (en) 1979-12-20 1982-10-26 The Mead Corporation Encapsulation process
US4265874A (en) 1980-04-25 1981-05-05 Alza Corporation Method of delivering drug with aid of effervescent activity generated in environment of use
US4438119A (en) 1982-12-23 1984-03-20 Mead Johnson & Company Method for alleviation of extrapyramidal motor disorders
US4640921A (en) 1986-02-04 1987-02-03 Bristol-Myers Treatment of sexual dysfunction with buspirone
US4832957A (en) 1987-12-11 1989-05-23 Merck & Co., Inc. Controlled release combination of carbidopa/levodopa
US4687772A (en) 1986-10-07 1987-08-18 Bristol-Myers Company Method for improvement of short term memory
US4777173A (en) 1987-03-25 1988-10-11 Bristol-Myers Company Method for treatment of alcohol abuse
US5185329A (en) 1988-08-30 1993-02-09 Bristol-Myers Squibb Company Method for treatment of substance addiction
US6432956B1 (en) 1990-02-12 2002-08-13 William C. Dement Method for treatment of sleep apneas
CZ288351B6 (en) 1990-06-07 2001-05-16 Astrazeneca Ab Nitrogenous heterocyclic compound, process of its preparation and use as well as a medicament containing thereof
US5633009A (en) 1990-11-28 1997-05-27 Sano Corporation Transdermal administration of azapirones
US5431922A (en) 1991-03-05 1995-07-11 Bristol-Myers Squibb Company Method for administration of buspirone
DE4122217C2 (de) 1991-07-04 1997-02-13 Merz & Co Gmbh & Co Verfahren zur Herstellung mechanisch stabiler, gut zerfallender Komprimate aus kleinen wirkstoffhaltigen Formkörpern
GB9209882D0 (en) 1992-05-07 1992-06-24 Glaxo Lab Sa Compositions
US5484788A (en) 1993-03-26 1996-01-16 Beth Israel Hospital Association Buspirone as a systemic immunosuppressant
US5637314A (en) 1995-06-07 1997-06-10 Beth Israel Deaconess Medical Center, Inc. Topical and systemic application of buspirone or derivatives thereof for treating atopic dermatitis
GB9816556D0 (en) 1998-07-30 1998-09-30 Pfizer Ltd Therapy
US20080118556A1 (en) * 1998-11-02 2008-05-22 Elan Corporation, Plc Modified Release of Compositions Containing a Combination of Carbidopa, Levodopa and Entacapone
FI109453B (fi) * 1999-06-30 2002-08-15 Orion Yhtymae Oyj Farmaseuttinen koostumus
US6150365A (en) 1999-08-05 2000-11-21 Bristol-Myers Squibb Company Anxiety method
GB9928578D0 (en) 1999-12-03 2000-02-02 Zeneca Ltd Pharmaceutical formulations
US6627223B2 (en) 2000-02-11 2003-09-30 Eurand Pharmaceuticals Ltd. Timed pulsatile drug delivery systems
WO2002044159A2 (en) 2000-11-29 2002-06-06 Eli Lilly And Company 1-(2-m-methanesulfonamidophenylethyl)-4-(m-trifluoromethylphenyl)piperazine and pharmaceutically acceptable salts and solvates thereof and their use in the treatment of incontinence
WO2002053139A2 (en) 2001-01-05 2002-07-11 Eli Lilly And Company Excitatory amino acid receptor antagonist and 5-ht1f agonist combination: a method for the treatment of neurological disorders
US20030035839A1 (en) * 2001-05-15 2003-02-20 Peirce Management, Llc Pharmaceutical composition for both intraoral and oral administration
US8329734B2 (en) 2009-07-27 2012-12-11 Afgin Pharma Llc Topical therapy for migraine
BR0211317A (pt) 2001-07-04 2004-12-14 Sun Pharmaceutical Ind Ltd Sistema para a liberação controlada de uma droga por meio de retenção gástrica
DE60211186T2 (de) 2001-09-19 2007-01-18 Merck Patent Gmbh Neue verwendung substituierter aminomethylchromane
KR20050016449A (ko) * 2002-05-29 2005-02-21 임팩스 라보라토리즈, 인코포레이티드 레보도파/카르비도파의 즉시 방출 및 제어 방출 조합 투여형
US7094427B2 (en) 2002-05-29 2006-08-22 Impax Laboratories, Inc. Combination immediate release controlled release levodopa/carbidopa dosage forms
US20030224045A1 (en) * 2002-05-29 2003-12-04 Chien-Hsuan Han Combination immediate release sustained release levodopa/carbidopa dosage forms
CA2541382A1 (en) 2003-10-10 2005-04-21 Lifecycle Pharma A/S A solid dosage form comprising a fibrate and a statin
US7470435B2 (en) 2003-11-17 2008-12-30 Andrx Pharmaceuticals, Llc Extended release venlafaxine formulation
DE10353657A1 (de) 2003-11-17 2005-06-23 Merck Patent Gmbh Indolderivate
EP1711493A2 (en) 2004-02-06 2006-10-18 CIBA SPECIALTY CHEMICALS HOLDING INC. Patent Departement Crystalline forms of zolmitriptan
US20070155755A1 (en) 2004-02-23 2007-07-05 Wei Edward T N-arylshydroxyalkylidene-carboxamide compositions and methods
WO2006014427A1 (en) 2004-07-02 2006-02-09 Advancis Pharmaceutical Corporation Tablet for pulsed delivery
CA2578990A1 (en) 2004-09-07 2006-03-16 Pfizer Inc. Combination of a 5-ht(1) receptor agonist and an alpha-2-delta ligand for the treatment of migraine
EP2623099A1 (en) * 2004-11-24 2013-08-07 Neuromolecular Pharmaceuticals, Inc Composition and method for treating neurological disease
EP1856100B1 (en) 2005-01-18 2010-05-05 Merck Sharp & Dohme Corp. Cgrp receptor antagonists
US20080166407A1 (en) 2005-07-29 2008-07-10 Shalaby Shalaby W Solid oral formulations for combination therapy
US9066903B2 (en) 2006-02-28 2015-06-30 The United States Of America As Represented By The Department Of Veterans Affairs Pharmacological treatment of Parkinson's disease
WO2007129329A2 (en) 2006-05-08 2007-11-15 Jubilant Organosys Limited Extended release pharmaceutical formulation comprising venlafaxine hydrochloride
US7678808B2 (en) 2006-05-09 2010-03-16 Braincells, Inc. 5 HT receptor mediated neurogenesis
WO2007144422A2 (en) 2006-06-16 2007-12-21 Solvay Pharmaceuticals B.V. Combination preparations comprising bifeprunox and l-dopa
WO2008033155A1 (en) 2006-09-15 2008-03-20 Auriga Laboratories, Inc. Kits for prevention and treatment of rhinitis
WO2008047839A1 (en) 2006-10-19 2008-04-24 Dainippon Sumitomo Pharma Co., Ltd. 5-ht1a receptor agonist
CA2673511A1 (en) * 2006-12-22 2008-07-03 Combinatorx, Incorporated Pharmaceutical compositions for treatment of parkinson's disease and related disorders
WO2008115797A1 (en) 2007-03-16 2008-09-25 Pavo, Inc. Therapeutic compositions and methods
CN101686942B (zh) 2007-06-27 2012-09-26 韩美药品株式会社 用于快速制备用于口服的崩解剂的方法及其产品
NZ602302A (en) 2007-12-28 2014-04-30 Impax Laboratories Inc Controlled release formulations of levodopa and uses thereof
KR101444979B1 (ko) 2008-02-06 2014-10-07 욱크하르트 리미티드 생체 이용율이 개선된 엔타카폰, 레보도파 및 카르비도파의 약학 조성물
EP2105130A1 (de) 2008-03-25 2009-09-30 Ratiopharm GmbH Pharmazeutische Formulierung und Verfahren zu deren Herstellung
DK2276473T3 (en) 2008-04-18 2017-01-09 Intec Pharma Ltd GASTRORETENTIV drug TO carbidopa / levodopa
WO2009156380A1 (en) 2008-06-24 2009-12-30 Bjoerklund Anders Eltoprazine for suppression of l-dopa induced dyskinesias
PT2361081T (pt) 2008-10-14 2016-09-05 Mcneil Ab Forma de dosagem intra-oral multiporção e seu uso
EA026651B1 (ru) 2009-01-23 2017-05-31 Ацьенде Кимике Рьюните Анджелини Франческо А.К.Р.А.Ф. С.П.А. Фармацевтический или пищевой состав с контролируемым высвобождением и способ его получения
SG181896A1 (en) 2009-12-23 2012-07-30 Map Pharmaceuticals Inc Novel ergoline analogs
CN101987081B (zh) * 2010-07-16 2012-08-08 钟术光 一种控释制剂
CN103402514B (zh) 2010-10-15 2016-01-13 康特拉医药公司 用于治疗运动障碍的血清素受体激动剂组合物
US20140017303A1 (en) 2010-11-01 2014-01-16 Intec Pharma Ltd. Accordion pill comprising levodopa for an improved treatment of parkinson's disease symptoms
WO2012163365A1 (en) 2011-06-01 2012-12-06 Concit Pharma Aps Combinations of serotonin receptor agonists for treatment of movement disorders
US20130195973A1 (en) 2012-01-30 2013-08-01 Ranbaxy Laboratories Limited Extended release pharmaceutical dosage forms of carbidopa and levodopa and process of preparation thereof
CA2973701A1 (en) 2015-01-13 2016-07-21 Amarantus Bioscience Holdings, Inc. Methods of treating motor and movement disorders and side effects thereof associated with parkinson's disease treatments
CN109689036B (zh) * 2016-07-11 2026-06-19 康特拉医药股份有限公司 用于治疗早晨运动不能的脉冲药物输送系统

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101636153A (zh) * 2007-03-15 2010-01-27 波利化学公司 时间特异性延迟/脉冲释放剂型

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
The effects of carbidopa dose and time and route of administration on systemic L-dopa levels in rats;P S Leppert et al.;《Pharmaceutical Research 》;19880930;第5卷(第9期);第509页 *

Also Published As

Publication number Publication date
CA3030089C (en) 2024-04-23
US20190290587A1 (en) 2019-09-26
EP4674433A2 (en) 2026-01-07
EP3481385C0 (en) 2025-09-03
AU2017297718B2 (en) 2023-06-08
US20230078925A1 (en) 2023-03-16
AU2023206140A1 (en) 2023-08-10
AU2023206140B2 (en) 2025-05-29
AU2017297718A1 (en) 2019-01-31
US11975104B2 (en) 2024-05-07
JP2019524727A (ja) 2019-09-05
US20250367123A1 (en) 2025-12-04
ES3041483T3 (en) 2025-11-12
JP7227896B2 (ja) 2023-02-22
JP2022120040A (ja) 2022-08-17
WO2018011181A1 (en) 2018-01-18
JP2024156827A (ja) 2024-11-06
AU2025223847A1 (en) 2025-09-18
CA3030089A1 (en) 2018-01-18
EP4674433A3 (en) 2026-04-01
KR102443161B1 (ko) 2022-09-14
CN109689036A (zh) 2019-04-26
KR20190026823A (ko) 2019-03-13
EP3481385A1 (en) 2019-05-15
JP7534354B2 (ja) 2024-08-14
EP3481385B1 (en) 2025-09-03

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
CB02 Change of applicant information

Address after: Dane Hess Holm

Applicant after: Cantra Pharmaceutical Co.,Ltd.

Applicant after: SOLURAL PHARMA APS

Address before: Copenhagen, Denmark

Applicant before: CONCIT PHARMA APS

Applicant before: SOLURAL PHARMA APS

CB02 Change of applicant information
TA01 Transfer of patent application right

Effective date of registration: 20221129

Address after: Dane Hess Holm

Applicant after: Cantra Pharmaceutical Co.,Ltd.

Address before: Dane Hess Holm

Applicant before: Cantra Pharmaceutical Co.,Ltd.

Applicant before: SOLURAL PHARMA APS

TA01 Transfer of patent application right
GR01 Patent grant
GR01 Patent grant